Vertex Pharmaceuticals Inc
VRTX483.295USD
-8.344-1.69%
Horarios del mercado 03/06, 12:59（ET）Cotizaciones retrasadas 15 min
124.17BCap. mercado
-231.85P/E TTM
Información de Vertex Pharmaceuticals Inc Compañía
Información de la empresa
Código de la empresaVRTX
Nombre de la empresaVertex Pharmaceuticals Inc
Fecha de salida a bolsaJul 24, 1991
Fundada en1989
Director ejecutivoDr. Reshma Kewalramani
Número de empleados6100
Tipo de títulosOrdinary Share
Fin del año fiscalJul 24
Dirección50 Northern Avenue
CiudadBOSTON
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02210
Teléfono16173416393
Sitio Webhttps://www.vrtx.com/
Código de la empresaVRTX
Fecha de salida a bolsaJul 24, 1991
Fundada en1989
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionados
Cambio
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
40.00K
--
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
32.66K
+40.46%
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
30.14K
--
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
25.25K
+59.69%
Mr. Stuart A. Arbuckle
Mr. Stuart A. Arbuckle
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
17.10K
+342.84%
Mr. Lloyd A. Carney
Mr. Lloyd A. Carney
Independent Director
Independent Director
6.31K
+18.82%
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Independent Director
Independent Director
4.43K
--
Ms. Diana L. Mckenzie
Ms. Diana L. Mckenzie
Independent Director
Independent Director
1.47K
-10.17%
Mr. Michel Lagarde
Mr. Michel Lagarde
Independent Director
Independent Director
1.13K
--
Ms. Kristen Ambrose
Ms. Kristen Ambrose
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionados
Cambio
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
40.00K
--
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
32.66K
+40.46%
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
30.14K
--
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
25.25K
+59.69%
Mr. Stuart A. Arbuckle
Mr. Stuart A. Arbuckle
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
17.10K
+342.84%
Mr. Lloyd A. Carney
Mr. Lloyd A. Carney
Independent Director
Independent Director
6.31K
+18.82%
Desglose de ingresos
Divisa: USDHora de actualización: mié., 5 de mar
Divisa: USDHora de actualización: mié., 5 de mar
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por negocioUSD
Nombre
Ganancia
Proporción
TRIKAFTA
10.23B
92.90%
Other CF products
781.50M
7.09%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
6.68B
60.66%
Europe
3.45B
31.34%
Other
881.30M
7.99%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
TRIKAFTA
10.23B
92.90%
Other CF products
781.50M
7.09%
Accionista
Hora de actualización: vie., 21 de feb
Hora de actualización: vie., 21 de feb
Estadísticas de accionistas
Tipo
Estadísticas de accionistas
Accionista
Proporción
Capital World Investors
11.03%
The Vanguard Group, Inc.
9.01%
BlackRock Institutional Trust Company, N.A.
5.57%
State Street Global Advisors (US)
4.66%
Capital Research Global Investors
4.06%
Other
65.64%
Estadísticas de accionistas
Accionista
Proporción
Capital World Investors
11.03%
The Vanguard Group, Inc.
9.01%
BlackRock Institutional Trust Company, N.A.
5.57%
State Street Global Advisors (US)
4.66%
Capital Research Global Investors
4.06%
Other
65.64%
Tipo
Accionista
Proporción
Investment Advisor
49.08%
Investment Advisor/Hedge Fund
37.63%
Pension Fund
2.66%
Research Firm
2.13%
Bank and Trust
1.87%
Hedge Fund
1.44%
Sovereign Wealth Fund
1.43%
Holding Company
0.19%
Individual Investor
0.12%
Other
3.41%
Participación institucional
Hora de actualización: dom., 19 de ene
Hora de actualización: dom., 19 de ene
Periodo de informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
2803
248.60M
96.81%
-2.22M
2024Q4
2877
248.75M
96.87%
-2.25M
2024Q3
2786
247.86M
96.18%
-4.19M
2024Q2
2747
248.35M
96.27%
-4.14M
2024Q1
2680
247.62M
95.87%
-4.47M
2023Q4
2608
247.92M
96.20%
-4.51M
2023Q3
2477
248.64M
96.45%
-6.19M
2023Q2
2488
248.88M
96.55%
-7.10M
2023Q1
2468
250.11M
97.13%
-4.73M
2022Q4
2454
248.59M
96.73%
-7.79M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Capital World Investors
28.32M
11.03%
+1.51M
+5.65%
Dec 31, 2024
The Vanguard Group, Inc.
23.14M
9.01%
+102.47K
+0.44%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
14.32M
5.57%
-90.57K
-0.62%
Dec 31, 2024
State Street Global Advisors (US)
11.97M
4.66%
+163.15K
+1.38%
Dec 31, 2024
Capital Research Global Investors
10.42M
4.06%
+1.42M
+15.84%
Dec 31, 2024
Fidelity Management & Research Company LLC
9.10M
3.54%
-1.25M
-12.06%
Dec 31, 2024
Wellington Management Company, LLP
5.91M
2.3%
+1.11M
+23.28%
Dec 31, 2024
Geode Capital Management, L.L.C.
5.64M
2.19%
-287.65K
-4.84%
Dec 31, 2024
Invesco Capital Management (QQQ Trust)
5.22M
2.03%
+92.09K
+1.79%
Dec 31, 2024
JP Morgan Asset Management
4.61M
1.79%
-403.92K
-8.04%
Dec 31, 2024
Ver más
ETF relacionados
Hora de actualización: hace 17 horas
Hora de actualización: hace 17 horas
Nombre
Proporción
Future Fund Active ETF
13.69%
VanEck Biotech ETF
11.53%
ProShares Ultra Nasdaq Biotechnology
8.36%
Invesco Nasdaq Biotechnology ETF
7.92%
Tema Neuroscience and Mental Health ETF
7.19%
iShares Biotechnology ETF
6.84%
Natixis Loomis Sayles Focused Growth ETF
5.03%
Franklin Genomic Advancements ETF
4.8%
Tema Cardiovascular and Metabolic ETF
4.37%
First Trust NYSE Arca Biotechnology Index Fund
3.64%
Ver más
Future Fund Active ETF
Proporción13.69%
VanEck Biotech ETF
Proporción11.53%
ProShares Ultra Nasdaq Biotechnology
Proporción8.36%
Invesco Nasdaq Biotechnology ETF
Proporción7.92%
Tema Neuroscience and Mental Health ETF
Proporción7.19%
iShares Biotechnology ETF
Proporción6.84%
Natixis Loomis Sayles Focused Growth ETF
Proporción5.03%
Franklin Genomic Advancements ETF
Proporción4.8%
Tema Cardiovascular and Metabolic ETF
Proporción4.37%
First Trust NYSE Arca Biotechnology Index Fund
Proporción3.64%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
No datos encontrados
División de acciones
Fecha
Tipo
Relación
No datos encontrados
Fecha
Tipo
Relación
No datos encontrados